Thankful for the chance to sit with replay sessions from the Goldman Sachs 47th Annual Global Healthcare Conference.
Most people spend their careers becoming fluent in either the science of medicine or the language of markets. Very few have the opportunity to become fluent in both, and that's where some of healthcare's most important conversations begin. And today, that fluency matters more than ever.
A therapy's clinical promise is only half the story, the other half is whether the market believes in it enough to bring it to patients. Hearing leaders from Johnson & Johnson, Pfizer, Merck, Amgen, and other industry pioneers discuss this intersection was eye opening, revealing how scientific innovation, investment, and capital allocation shape the future of healthcare. Here are a few takeaways I'm carrying forward:
1. Innovation doesn't scale without capital, and capital doesn't move without confidence in the science. They're one feedback loop, not two independent industries.
2. In tighter markets, the companies that survive aren't always the ones with the best science, they're the ones who communicate value clearly enough to keep earning investment.
3. My advantage as a student isn't choosing a side. It's building fluency in both, so I can see where they're about to collide before everyone else does.
The more people entering this field understand that link, the better we can push for a system where capital rewards genuine patient impact, closing the gap between good science and the outcomes patients actually deserve.
